BACKGROUND: After delivery, many women experience symptoms of postpartum depression (PPD), and early identification of women at risk is therefore important. The opioid peptide beta-endorphin has been implicated in non-puerperal depression but its role in the development of PPD is unknown. METHODS: Three hundred and seven women with a singleton, full-term (>37.0 weeks' GA) pregnancy were recruited early in pregnancy and followed up into the postpartum period. Blood samples were obtained at 15, 19, 25, 31 and 37 weeks' gestational age (GA) and at 9 weeks postpartum for assessment of beta-endorphin. Depressive symptoms were assessed with the Center for Epidemiological Studies-Depression scale at the last four pregnancy visits and with the Edinburgh Postnatal Depression Scale postpartum. RESULTS: Among women who were euthymic at 25 weeks' GA, those who proceeded to develop PPD symptoms had higher levels of beta-endorphin throughout pregnancy compared to women without PPD symptoms (all t>2.11, p<.05). At each assessment, women above the cut-off score for beta-endorphin were at more than three-fold risk for PPD symptoms (odds ratios 3.19-4.68) compared to women below the cut-off score. LIMITATIONS: Self-report of depressive symptoms, no mental health history. CONCLUSIONS: Beta-endorphin may be a useful early predictor of PPD symptoms in women who do not report depressive symptoms in mid-pregnancy. If replicated, these findings have clinical implications for the identification and treatment of this at-risk group and further suggest that some of the pathways leading to this complex disorder may be specific to subgroups of women. 2009 Elsevier B.V. All rights reserved.
BACKGROUND: After delivery, many women experience symptoms of postpartum depression (PPD), and early identification of women at risk is therefore important. The opioid peptide beta-endorphin has been implicated in non-puerperal depression but its role in the development of PPD is unknown. METHODS: Three hundred and seven women with a singleton, full-term (>37.0 weeks' GA) pregnancy were recruited early in pregnancy and followed up into the postpartum period. Blood samples were obtained at 15, 19, 25, 31 and 37 weeks' gestational age (GA) and at 9 weeks postpartum for assessment of beta-endorphin. Depressive symptoms were assessed with the Center for Epidemiological Studies-Depression scale at the last four pregnancy visits and with the Edinburgh Postnatal Depression Scale postpartum. RESULTS: Among women who were euthymic at 25 weeks' GA, those who proceeded to develop PPD symptoms had higher levels of beta-endorphin throughout pregnancy compared to women without PPD symptoms (all t>2.11, p<.05). At each assessment, women above the cut-off score for beta-endorphin were at more than three-fold risk for PPD symptoms (odds ratios 3.19-4.68) compared to women below the cut-off score. LIMITATIONS: Self-report of depressive symptoms, no mental health history. CONCLUSIONS:Beta-endorphin may be a useful early predictor of PPD symptoms in women who do not report depressive symptoms in mid-pregnancy. If replicated, these findings have clinical implications for the identification and treatment of this at-risk group and further suggest that some of the pathways leading to this complex disorder may be specific to subgroups of women. 2009 Elsevier B.V. All rights reserved.
Authors: Rudolf Likar; Shaaban A Mousa; Hermann Steinkellner; Wolfgang Koppert; Gudrun Philippitsch; Christoph Stein; Michael Schäfer Journal: Clin J Pain Date: 2007-02 Impact factor: 3.442
Authors: Lauren M Ellman; Christine Dunkel Schetter; Calvin J Hobel; Aleksandra Chicz-Demet; Laura M Glynn; Curt A Sandman Journal: Dev Psychobiol Date: 2008-04 Impact factor: 3.038
Authors: Mary Kimmel; Makena Clive; Fiona Gispen; Jerry Guintivano; Tori Brown; Olivia Cox; Matthias W Beckmann; Johannes Kornhuber; Peter A Fasching; Lauren M Osborne; Elisabeth Binder; Jennifer L Payne; Zachary Kaminsky Journal: Psychoneuroendocrinology Date: 2016-04-08 Impact factor: 4.905
Authors: Zach J Gray; Grant S Shields; Stassja Sichko; Theresa Q Bui; Meghan Vinograd; Hector A Olvera-Alvarez; George M Slavich Journal: Compr Psychoneuroendocrinol Date: 2022-06-16